



Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017

More than **80 presentations** (including 16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning **20 types of cancer**, with focus on research of precision therapies aimed at improving standards of care. The presentations represent the breadth of the Company's Oncology research portfolio, including monotherapy and combination studies of **Opdivo and Yervoy, as well as studies of Empliciti and Sprycel**.

The Company will also present updates from its robust investigational pipeline, including proof-of-concept efficacy data for its **anti-LAG-3 mab in combination with Opdivo** and PK/PD and safety data on its investigational glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR) agonist alone and for the first time, in combination with Opdivo in advanced solid tumors.

Several presentations will report data from clinical collaborations supportive of the Company's efforts to advance understanding of the potential role for **Opdivo in combination with novel moAs for several tumor types**, including the first presentation of data evaluating the safety and efficacy of Opdivo in combination with epacadostat, Incyte's selective IDO1 enzyme inhibitor. Presentations featuring translational medicine research underscore BMS's scientific leadership in driving understanding of how a patient's tumor biology can potentially guide treatment decisions.

Key Presentations

Gastrointestinal malignancies	<ul style="list-style-type: none"> nivo + ipi in the treatment of dMMR/MSI-H mCRC: CheckMate 142 study (Abstract 3531) Concordance of local and central assessment of DNA mismatch repair deficient/microsatellite instability, in mCRC patients receiving nivolumab in CheckMate 142 (Abstract 3548) Nivolumab in sorafenib-naive and -experienced patients with advanced HCC: The CheckMate 040 study (Abstract 4013) CheckMate 649: phase 3 study of nivo + ipi or nivo + CTX vs CTX alone in 1st Line GEJ cancer (Abstract TPS4132) Nivo ± ipi in patients with CTX-refractory gastric, esophageal or GEJ cancer: CheckMate 032 study (Abstract 4014)
Genitourinary Cancer	<ul style="list-style-type: none"> HRQOL as a marker of treatment benefit with nivolumab in platinum-refractory patients with unresectable or mUC from CheckMate 275 (Abstract 4526)
Glioblastoma	<ul style="list-style-type: none"> CheckMate 143: Suspected disease progression in nivo ± ipi treated recurrent GBM patients: (Abstract 2001) OS by line of therapy in Medicare-enrolled GBM patients (Abstract 2039)
Gynecologic Cancers	<ul style="list-style-type: none"> An OL, multicohort, phase 1/2 study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety (Abstract 5504)
Head and Neck Cancer	<ul style="list-style-type: none"> Nivolumab vs investigator's choice for platinum-refractory recurrent or mSCCHN (Checkmate 141): Outcomes in first-line R/M patients and updated safety and efficacy (Abstract 6019) An OL, multicohort, phase 1/2 study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic nasopharyngeal carcinoma (Abstract 6025) Characterization of potential predictive biomarkers of SCCHN response to nivolumab in CheckMate 141 (Abstract 6050)
Heamatologic malignancies	<ul style="list-style-type: none"> Phase 2 trial of dasatinib in pediatric CML patients in chronic phase (Abstract 10511) Impact of dose reductions on 5-year efficacy in newly diagnosed CML patients (Abstract 7051) Phase 3 ELOQUENT-2 study: Extended 4-year follow-up of elotuzumab + lenalidomide/ dexamethasone vs Ld in R/R MM (Abstract 8028) Nivolumab + daratumumab, +/- pomalidomide and dexamethasone, for R/R MM: 2 cohorts of the phase 1 CheckMate 039 safety study (Abstract TPS3102) CheckMate 436: Efficacy of nivolumab + brentuximab vedotin in CD30-expressing R/R NHL (Abstract TPS7577) CheckMate 602: An OL Phase 3 RCT of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in R/R MM (Abstract TPS8052)
Melanoma	<ul style="list-style-type: none"> OS analysis from a nivo+ipi expanded access program of in adv. Melanoma patients (CheckMate 218) (Abstract 9522) Baseline tissue biomarkers and association with response to nivo+ipi in melanoma: CheckMate 064 (Abstract 9515) Management of GI toxicity associated with nivo+ipi or ipi alone in phase 2 and 3 trials in adv. melanoma (Abstract 9523) Efficacy and safety of nivolumab in patients with advanced melanoma and poor prognostic factors who progressed on or after ipilimumab: Results from a phase 2 study (CheckMate 172) (Abstract 9524)
Thoracic malignancies	<ul style="list-style-type: none"> Nivolumab plus ipilimumab as first-line treatment for advanced NSCLC: 2-year OS and long-term outcomes from CheckMate 012 (Abstract 9093) Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC (Abstract TPS8577) Checkmate 743: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma (Abstract 8581)
	<ul style="list-style-type: none"> FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A OL adaptive 2 RCT of nivo+ immuno-oncology agents in patients with advanced GC (Abstract TPS4137) Initial efficacy of BMS-986016(anti-LAG-3) + nivo in patients with anti-PD-1/L1 pre-treated Melanoma (Abstract 9520) Prelim. phase 1/2a results of BMS-986156 (GITR agonist), +/- nivo in patients with advanced solid tumors (Abstract 104) nivo + nab-paclitaxel (nab-P) + carboplatin (C) in NSCLC patients: Phase I study's interim results. (Abstract 9095) Ceritinib plus nivo in patients with ALK+ NSCLC (Abstract 2502) Effect of NKTR-214 (anti-IL2) on proliferating CD8+T cells and IC PD-1 expr. in ICI pre-treated patients (Abstract 2545) A phase I study of enadenotucirev (an oncolytic Ad11/Ad3 adenovirus) + nivo in tumors of epithelial origin (TPS3115) Varlilumab (anti-CD27)+ nivolumab in advanced cancer patients (Abstract 3007)
International Immuno-Oncology Network (II-ON)	<ul style="list-style-type: none"> Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance, smoldering MM and tumor-specific T lymphocytes (Abstract 11577) Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in mRCC (Abstract 3016) Metabolomic correlates of response in nivolumab-treated RCC and melanoma patients (Abstract 3036)